Premium
Targeted therapies in metastatic renal cancer in 2009
Author(s) -
Bastien Laurence,
Culine Stéphane,
Paule Bernard,
Ledbai Souhil,
Patard Jean Jacques,
De La Taille Alexandre
Publication year - 2009
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.08454.x
Subject(s) - sunitinib , temsirolimus , sorafenib , targeted therapy , bevacizumab , medicine , renal cell carcinoma , vascular endothelial growth factor , cancer research , oncology , cancer , pharmacology , vegf receptors , discovery and development of mtor inhibitors , pi3k/akt/mtor pathway , biology , signal transduction , hepatocellular carcinoma , chemotherapy , biochemistry
The development of targeted molecules in renal carcinogenesis changed the therapeutic approaches of treatment for metastatic clear cell renal cell carcinoma. Four available drugs are currently available, i.e. bevacizumab, sunitinib, sorafenib and temsirolimus, but other molecules and combined therapy are under investigation. In this review we assess published reports of these targeted therapies and discuss the novel promising molecules targeting vascular endothelial growth factor and its receptors, the mammalian target of rapamycin and epithelial growth factor cascade.